HOT-7
HOT-7
Names
Preferred IUPAC name
2-[2,5-Dimethoxy-4-(propylsulfanyl)phenyl]-N -hydroxyethan-1-amine
Other names
2-[4-(Propylthio)-2,5-dimethoxyphenyl]ethanaminol
Identifiers
ChEMBL
ChemSpider
UNII
InChI=1S/C13H21NO3S/c1-4-7-18-13-9-11(16-2)10(5-6-14-15)8-12(13)17-3/h8-9,14-15H,4-7H2,1-3H3
Y Key: ASTNLROMDNGJLS-UHFFFAOYSA-N
Y InChI=1/C13H21NO3S/c1-4-7-18-13-9-11(16-2)10(5-6-14-15)8-12(13)17-3/h8-9,14-15H,4-7H2,1-3H3
Key: ASTNLROMDNGJLS-UHFFFAOYAX
Properties
C13 H21 NO3 S
Molar mass
271.374 g/mol
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
Chemical compound
HOT-7 , or 2,5-dimethoxy-4-(β-propylthio)-N-hydroxyphenethylamine , is a psychedelic phenethylamine of the 2C family . It was presumably first synthesized by Alexander Shulgin and reported in his book, PiHKAL .[ 1]
Chemistry
HOT-7's full chemical name is 2-[4-(2-propyl thio )-2,5-dimethoxy phenyl –N –hydroxyethanamine . It has structural properties similar to 2C-T-7 and to other drugs in the HOT- series, with the most closely related compounds being HOT-2 and HOT-17 .
The dosage range of HOT-7 is typically 15-25 mg and its duration is approximately 6–8 hours according to Shulgin.[ 1] HOT-7 produces closed-eye and open-eye visuals. It also induces a feeling similar to that of being drunk .
Legality
United Kingdom
This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act .[ 2]
See also
References
Psychedelics (5-HT2A agonists)
Benzofurans Lyserg‐ amides Phenethyl‐ amines
2C-x
3C-x 4C-x DOx HOT-x MDxx Mescaline (subst.) TMAs
TMA
TMA-2
TMA-3
TMA-4
TMA-5
TMA-6
Others
Piperazines Tryptamines
alpha -alkyltryptaminesx -DALT x -DET x -DiPT x -DMT
4,5-DHP-DMT
2,N,N-TMT
4-AcO-DMT
4-HO-5-MeO-DMT
4,N,N-TMT
4-Propionyloxy-DMT
5,6-diBr-DMT
5-AcO-DMT
5-Bromo-DMT
5-MeO-2,N ,N -TMT
5-MeO-4,N ,N -TMT
5-MeO-α,N,N-TMT
5-MeO-DMT
5-N ,N -TMT
7,N,N-TMT
α,N,N-TMT
(Bufotenin) 5-HO-DMT
DMT
Norbaeocystin
(Psilocin) 4-HO-DMT
(Psilocybin) 4-PO-DMT
x -DPT Ibogaine-related x -MET x -MiPT Others
Others
Dissociatives (NMDAR antagonists )
Deliriants (mAChR antagonists ) Others